Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

131 ARTÍCULOS , VIENDO DEL 31 AL 45

The serum protein and lipid oxidation marker levels in Alzheimer's disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy

Sinem F, Dildar K, Gökhan E, Melda B, Orhan Y, Filiz M.

Curr Alzheimer Res. 2010 Aug;7(5):463-9. doi: 10.2174/156720510791383822.

The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia

Spies PE, Slats D, Sjögren JM, Kremer BP, Verhey FR, Rikkert MG, Verbeek MM.

Curr Alzheimer Res. 2010 Aug;7(5):470-6. doi: 10.2174/156720510791383796.

Imaging and biomarkers for Alzheimer's disease

Allan CL, Sexton CE, Welchew D, Ebmeier KP.

Maturitas. 2010 Feb;65(2):138-42. doi: 10.1016/j.maturitas.2009.12.006. Epub 2010 Jan 8.

Apolipoprotein E promoter polymorphisms and risk of Alzheimer's disease: evidence from meta-analysis

Xin XY, Ding JQ, Chen SD.

J Alzheimers Dis. 2010;19(4):1283-94. doi: 10.3233/JAD-2010-1329.

[Pathobiology of Alzheimer's disease and biomarker development]

Arai H, Okamura N, Waragai M, Furukawa K, Yanai K, Kudo Y.

Nihon Yakurigaku Zasshi. 2010 Jan;135(1):3-7. doi: 10.1254/fpj.135.3.

NEP-like endopeptidases and Alzheimer's disease [corrected]

Marr RA, Spencer BJ.

Curr Alzheimer Res. 2010 May;7(3):223-9. doi: 10.2174/156720510791050849.

Imaging as a strategy for premortem diagnosis and staging of tauopathies

Kim S, Jensen JR, Cisek K, Funk KE, Naphade S, Schafer K, Kuret J.

Curr Alzheimer Res. 2010 May;7(3):230-4. doi: 10.2174/156720510791050894.

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

Blennow K, Hampel H, Weiner M, Zetterberg H.

Nat Rev Neurol. 2010 Mar;6(3):131-44. doi: 10.1038/nrneurol.2010.4. Epub 2010 Feb 16.

Frontal variant of Alzheimer's disease: clinico-CSF-pathological correlation

Habek M, Hajnsek S, Zarković K, Chudy D, Mubrin Z.

Can J Neurol Sci. 2010 Jan;37(1):118-20.

Microglia activation and anti-inflammatory regulation in Alzheimer's disease

Lue LF, Kuo YM, Beach T, Walker DG.

Mol Neurobiol. 2010 Jun;41(2-3):115-28. doi: 10.1007/s12035-010-8106-8. Epub 2010 Mar 3.

[Biomarkers in the cerebrospinal fluid of patients with mild cognitive impairment: a meta-analysis of their predictive capacity for the diagnosis of Alzheimer's disease]

Monge-Argilés JA, Sánchez-Payá J, Muñoz-Ruiz C, Pampliega-Pérez A, Montoya-Gutiérrez J, Leiva-Santana C.

Rev Neurol. 2010 Feb 16-28;50(4):193-200.

Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall

Mattsson N, Blennow K, Zetterberg H.

Clin Chem Lab Med. 2010 May;48(5):603-7. doi: 10.1515/CCLM.2010.131.

Impact of the CD40-CD40L dyad in Alzheimer's disease

Giunta B, Rezai-Zadeh K, Tan J.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):149-55. doi: 10.2174/187152710791012099.

Alzheimer's disease and retinal neurodegeneration

Guo L, Duggan J, Cordeiro MF.

Curr Alzheimer Res. 2010 Feb;7(1):3-14. doi: 10.2174/156720510790274491.

Advanced glycation end products as biomarkers and gerontotoxins - A basis to explore methylglyoxal-lowering agents for Alzheimer's disease?

Krautwald M, Münch G.

Exp Gerontol. 2010 Oct;45(10):744-51. doi: 10.1016/j.exger.2010.03.001. Epub 2010 Mar 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias